FDA
-
-
-
-
-
-
-
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annua
-
-
-
-
-
-
-
GRAIL integrates Galleri test into Epic health record platform
-
-
-
-
-
-
-
GRAIL, Inc. (GRAL) PT Lowered to $80 at Canaccord Genuity
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on GRAIL, Inc. (GRAL)
-
-
-
-
-
-
-
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
-
-
-
-
-
-
-
GRAIL, Inc. (GRAL) Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study
-
-
-
-
-
-
-
Canaccord Genuity Starts GRAIL, Inc. (GRAL) at Buy
-
326,431 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

